The sicilian network of biological therapy in inflammatory bowel disease: preliminary data from a prospective study on efficacy and safety by Orlando, A. et al.
Abstracts of the 23rd National Congress of Digestive Diseases / Digestive and Liver Disease 49S2 (2017) e73–e223 e91
respectively (Table A). Both PMS response and PMS remission, at Wk
2, were signiﬁcantly associated (p<0.0001) with clinical endpoints
at Wk 8 (Table B). Similar results were obtained in TNFi-naïve and
-experienced subpopulations.
Conclusions: In pts with moderate to severe UC treated with
tofacitinib 10 mg BID, tofacitinib demonstrated induction eﬃcacy
based on PMS as early as Wk 2, the ﬁrst time point measured
in this study. Eﬃcacy at Wk 2 is a good predictor of eﬃcacy at
Wk 8, regardless of prior TNFi therapy. Pts who have not achieved
remission or response at Wk 2 based on PMS may still achieve
improvements in Mayo score at Wk 8.
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Background and aim: The monitoring of appropriateness and costs
of biological therapy in Inﬂammatory bowel disease (IBD) is a
relevant need. We aimed to evaluate appropriateness, eﬃcacy and
safety of biological therapy in IBD in Sicily through a web based
network of prescribing centers.
Material and methods: The Sicilian network for the monitoring of
biological therapy in IBD is composed by a super Hub coordinator
center and ﬁve Hub plus ten Spoke centers. From January 2013
all IBD patients starting a biological agent (incident cases) or
already on treatment (prevalent cases) were entered in a web based
software. Herein we report data on remission and response after
twelve weeks of biological therapy, and side effects until the end of
follow-up of incident cases.
Results: From January 2013 to June 2016, 1475 patients were
included. Complete data were available in 1338 cases (983 with
Crohn’s disease [CD], 345 with ulcerative colitis [UC], and 10 with
unclassiﬁed colitis). Incident cases were 956 (673 CD, 274 UC, and
9 unclassiﬁed colitis). Considering that 12% of patients experienced
more than one line of therapy, a total of 1098 treatments were
reported. Adalimumab was used in 543 CD patients, in 69 UC
patients, and in 4 with unclassiﬁed colitis. Inﬂiximab was pre-
scribed in 221 CD patients (64 biosimilars), in 226 UC patients
(41 biosimilars), and in 5 patients with unclassiﬁed colitis. Goli-
mumab was prebscribed in 29 UC patients, and in 1 patient with
unclassiﬁed colitis. After twelve weeks, the rate of response with
Adalimumab was 46% and the rate of remission was 38% in CD,
while the rate of response with Inﬂiximab originator was 48% and
the rate of remission 42% (biosimilars: 37% and 50%, respectively).
In UC the rate of response with Adalimumab was 46% and the
rate of remission was 38%, the rate of response with Inﬂiximab
was 41% and the rate of remission 45% (biosimilars: 25% and 64%,
respectively), while the rate of response with Golimumab was 47%
and the rate of remission was 27%. Overall, the rate of side effects
was 17% (9.2% with Adalimumab, 20% with Inﬂiximab originator,
15% with biosimilars, and 17% with Golimumab).
Conclusions: In one of the largest series of IBD patients on
biological therapy reported to date, the rates of remission and re-
sponse after twelve weeks were comparable to data from literature,
and similar between the different biologics. Eﬃcacy and safety
of biosimilars were analogous to those reported for inﬂiximab
originator.
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Background and aim: Anti-tumor necrosis factor (anti-TNF) agents,
inﬂiximab (IFX) and more recently adalimumab (ADA) and goli-
mumab (GOL), have been shown effective and safe in the treatment
of moderate-to-severe ulcerative colitis (UC). Lack of head-to-head
RCTs makes the choice among the three anti-TNFs diﬃcult and
indirect comparisons lead to discrepant results. Our aim was to
compare eﬃcacy of IFX, ADA and GOL in inducing clinical response
and remission in a prospective cohort of patients with moderate to
severe UC.
Material and methods: From June 2015 to September 2016, 42
consecutive UC patients (25 male; mean age 42.1±16.9; mean
duration of disease 6.9±5.1 years) were treated: 14 with IFX, 14
with ADA and 14 with GOL. Disease activity was assessed by
Mayo Score. Clinical response and/or remission were evaluated at
week 8 and at week 16. We also recorded: indications to biologic
therapy, previous immunosuppressive or anti-TNF therapy and rate
of anti-TNF discontinuation.
Results: 29 patients were thiopurine failure; 28 were naïve to
anti-TNFs, most were treated with IFX (p=0.001). ADA and GOL
were more often used as a second-line or third-line. IFX was started
in 9 patients for steroid resistance and in 5 for steroid dependence;
all patients on ADA and GOL were steroid dependent. No signiﬁcant
difference was observed between IFX and ADA both at week 8 (re-
sponse p=0.40; remission p=0.71) and at week 16 (response p=0.28;
remission p=0.86), though there was a trend towards a higher rate
of response at week 8 with IFX (78.6% vs. 64.3%). Both IFX and ADA
were more effective than GOL at week 8 (response: IFX vs. GOL
p=0.006; ADA vs. GOL p=0.045; remission: IFX vs. GOL p=0.010; ADA
vs. GOL p=0.004). At week 16 only IFX seems to be more effective
